title: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
abstract: BACKGROUND
  In vitro studies of peritoneal dialysis (PD) solutions demonstrated that a biocompatible fluid with neutral-pH and low glucose degradation products (LF) has better biocompatibility than a conventional acidic lactate-buffered fluid (CF). However, few clinical trials have investigated the effects of the biocompatible solution on residual renal function (RRF). We performed a prospective, randomized trial with patients starting continuous ambulatory peritoneal dialysis (CAPD).
  
  
  METHODS
  Ninety-one incident patients started CAPD for 12-month treatment with either LF (Balance, Fresenius, n = 48) or CF (CAPD/DPCA, Fresenius, n = 43). RRF, peritoneal solute transport rate and solute clearance were measured every 6 months.
  
  
  RESULTS
  LF had a significant effect on the change of glomerular filtration rate (GFR) (P = 0.048 by the mixed model). In per-protocol analysis, GFR in the LF group did not decrease over a 12-month period, while GFR in the control group significantly decreased (0.13 +/- 33.4 L/ week/1.73 m(2) for LF versus -13.6 +/- 19.4 L/week/1.73 m(2) for CF, P = 0.049). Subgroup analysis for patients with initial GFR of 2 mL/min/1.73 m(2) or above showed a significantly higher GFR for the LF group over the 12-month period. At Month 13, serum total CO(2) levels were higher and serum albumin levels were lower in the LF group. No differences between the two groups were observed for the C-reactive protein. Over the 12-month period, effluent cancer antigen-125 levels significantly increased in the LF group, compared with those of the CF group, while effluent interleukin-6 levels were not different between the two groups.
  
  
  CONCLUSIONS
  Our study suggests that LF may better preserve RRF over the 12-month treatment period in incident CAPD patients.
authors.affiliation: Department of Internal Medicine, Gachon University of Medicine and Science, Incheon, Korea.
authors.forename: Sejoong
authors.initials: S
authors.lastname: Kim
authors.forename: Jieun
authors.initials: J
authors.lastname: Oh
authors.forename: Suhnggwon
authors.initials: S
authors.lastname: Kim
authors.forename: Wookyung
authors.initials: W
authors.lastname: Chung
authors.forename: Curie
authors.initials: C
authors.lastname: Ahn
authors.forename: Sung Gyun
authors.initials: SG
authors.lastname: Kim
authors.forename: Kook-Hwan
authors.initials: KH
authors.lastname: Oh
mesh_terms: D000328:Adult; D000368:Aged; D001672:Biocompatible Materials / Q000737:chemistry; D018394:CA-125 Antigen / Q000378:metabolism; D015314:Dialysis Solutions / Q000737:chemistry; D005260:Female; D005919:Glomerular Filtration Rate; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015850:Interleukin-6 / Q000378:metabolism; D007668:Kidney / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D008297:Male; D008422:Materials Testing; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D011446:Prospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D001672:Biocompatible Materials; D018394:CA-125 Antigen; D015314:Dialysis Solutions; C508600:IL6 protein, human; D015850:Interleukin-6; D005947:Glucose